Latest Health Insurance News

nib holdings limited reported a 9.4% increase in net profit after tax to $198.6 million for FY25, alongside a 7.8% rise in group revenue to $3.6 billion. Despite a dip in underlying operating profit, the company declared a fully franked final dividend, maintaining its full-year payout at 29 cents per share.

Pacific Smiles Group Limited reported a sharp 75.5% drop in statutory profit for FY 2025 due to one-off takeover expenses, yet underlying profit surged 38.6% on solid revenue growth and operational improvements.

One Click Group Limited has reported a record-breaking July with $3 million in revenue and $1.4 million in EBIT, marking a 34% increase on the prior period and profitability for the first seven months of 2025.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

EcoGraf Limited has advanced its vertically integrated battery anode materials business with a US$105 million financing mandate for its Epanko Graphite Mine and positive momentum in US and EU government support.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

One Click Group Limited has outpaced its entire July 2024 revenue within the first 18 days of July 2025, defying a broader decline in tax lodgements and showcasing strong customer loyalty.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.